Serotonin News and Research

Latest Serotonin News and Research

Antidepressant medications do not increase suicide risk in children

A Vanderbilt University Medical Center study released today shows there is no evidence that the risk of suicide differs with two commonly prescribed antidepressants prescribed to children and adolescents.

7 Jan 2014

Scientists discover new class of cells expressing olfactory receptors in human airways

Your nose is not the only organ in your body that can sense cigarette smoke wafting through the air. Scientists at Washington University in St. Louis and the University of Iowa have showed that your lungs have odor receptors as well.

3 Jan 2014

Study reveals why people are predisposed to cardiovascular disease and death

A genetic trait known to make some people especially sensitive to stress also appears to be responsible for a 38 percent increased risk of heart attack or death in patients with heart disease, scientists at Duke Medicine report.

19 Dec 2013

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.

11 Dec 2013

TAU researchers discover gene that may predict human responses to specific antidepressants

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants, but they don't work for everyone. What's more, patients must often try several different SSRI medications, each with a different set of side effects, before finding one that is effective.

9 Dec 2013

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.

6 Dec 2013

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

3 Dec 2013

Modafinil in combination with antidepressants reduces severity of depression more effectively

A new study has concluded that taking the drug modafinil, typically used to treat sleep disorders, in combination with antidepressants reduces the severity of depression more effectively than taking antidepressants alone.

28 Nov 2013

Scientists find possible new treatment for people with spinal cord injuries

Scientists may have found a new treatment that can help people with spinal cord injuries walk better. The research is published in the November 27, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology.

27 Nov 2013

Novel drug combats psychosis in Parkinson’s disease

The non-dopaminergic drug pimavanserin reduces psychotic symptoms in patients with Parkinson’s disease without worsening motor function, shows a randomized trial.

22 Nov 2013

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis.

15 Nov 2013

Study identifies patterns of brain activity associated with eating disorders

A growing body of evidence shows the impact of diet on brain function, and identifies patterns of brain activity associated with eating disorders such as binge eating and purging. The findings were presented at Neuroscience 2013, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

14 Nov 2013

Understanding the origins of delinquent and deviant behaviors

Physical and chemical changes in the brain during development can potentially play a role in some delinquent and deviant behaviors, according to research released today. Studies looking at the underlying mechanisms that influence our ability to exercise self-control were presented at Neuroscience 2013, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

13 Nov 2013

New view can give scientists better understanding of how antidepressants work in human brain

Research from Oregon Health & Science University's Vollum Institute, published in the current issue of Nature, is giving scientists a never-before-seen view of how nerve cells communicate with each other.

13 Nov 2013

Study: Infants attributed to sudden infant death syndrome may be due to brainstem abnormalities

Investigators at Boston Children's Hospital report that infants dying suddenly and unexpectedly, in both safe and unsafe sleep environments, have underlying brainstem abnormalities and are not all normal prior to death.

11 Nov 2013

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.

31 Oct 2013

Serotonin 2C receptors induce fast-acting antidepressant effects in mice

More than 1 in 10 Americans take antidepressants, but these medications can take weeks-and for some patients, months-before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.

29 Oct 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer Inc. (NYSE:PFE) announced top-line results from two phase 3b, placebo-controlled studies with Lyrica® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively.

19 Oct 2013

Findings shed light on the role of environmental event in development of neural circuits in newborns

Neurons that process sensory information such as touch and vision are arranged in precise, well-characterized maps that are crucial for translating perception into understanding. A study published by Cell Press on October 14 in the journal Developmental Cell reveals that the actual act of birth in mice causes a reduction in a brain chemical called serotonin in the newborn mice, triggering sensory maps to form.

16 Oct 2013

Serotonin News and Research

Latest Serotonin News and Research

Antidepressant medications do not increase suicide risk in children

Scientists discover new class of cells expressing olfactory receptors in human airways

Study reveals why people are predisposed to cardiovascular disease and death

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

TAU researchers discover gene that may predict human responses to specific antidepressants

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Modafinil in combination with antidepressants reduces severity of depression more effectively

Scientists find possible new treatment for people with spinal cord injuries

Novel drug combats psychosis in Parkinson’s disease

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

Study identifies patterns of brain activity associated with eating disorders

Understanding the origins of delinquent and deviant behaviors

New view can give scientists better understanding of how antidepressants work in human brain

Study: Infants attributed to sudden infant death syndrome may be due to brainstem abnormalities

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

e-Therapeutics begins ETS6103 phase IIb trial for major depressive disorder

Serotonin 2C receptors induce fast-acting antidepressant effects in mice

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Findings shed light on the role of environmental event in development of neural circuits in newborns

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Serotonin News and Research

Latest Serotonin News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in